ZNTL Zentalis Pharmaceuticals, Inc.: Earnings per share for the last 12 months

Zentalis Pharma (ZNTL) - corporate logo

Zentalis Pharmaceuticals (ZNTL) is implementing AI and robotics to accelerate the discovery of anti-tumor drugs, eliminating routine tasks for personnel. The market price action for EPS (TTM) is recorded at 7.50. The business relies on high global demand for targeted therapy. However, geopolitical tensions and sanctions are complicating reagent logistics, which could slow down the certification of new drugs and the execution of international trials.

Zentalis Pharmaceuticals Inc (ZNTL) Net earnings per share (EPS TTM): for the period 02/11/2024 - 11/18/2026

Financial and market metric breakdowns for Zentalis Pharmaceuticals Inc (ZNTL)

- current quotes and average value forecast:
Fundamental company valuation:ZNTL, Zentalis Pharmaceuticals, Inc.
Product sample of Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals' high authority in the field of targeted breast cancer therapy creates a foundation for ambitious market expectations. By analyzing the history of EPS YoY (TTM) percentage changes, an investor assesses the trailing twelve-month net income per share dynamics, which allows for the differentiation between accounting cycles and actual quotes to determine the asset's fair value.